DGFT Minutes
In force — no superseding record on file.
Government of India
Ministry of Commerce and Industry
DIRECTORATE GENERAL OF FOREIGN TRADE
Meeting No - NC/3/MEET/Dec/202122/12 Meeting Date - 17/12/2021
Minutes of the Norms Committee – 3 Meeting No. NC/3/MEET/Dec/202122/12 dated 17.12.2021, was actually held on 17.12.2021 and 07.01.2022 under the Chairmanship of Dr. Amiya Chandra, Addl. DGFT for considering the cases/issues under Duty Exemption Scheme (Chapter-4) of Foreign Trade Policy, 2015-20 pertaining to Chemical and Allied products falling under Chapter 29 and 30.
Following members were present in the Meeting:
| Sl.<br>No. | Name & Designation | Department |
|---|---|---|
| 1 | ShriShaish Kumar,Technical – 1 | Consultant |
| 2 | Shri D.N. Mathur,Technical – 2 | Consultant |
| In attendance | ||
| 1 | Shri AjayKumar,DeputyDirector | DGFT |
- The Norms Committee has taken decision only with respect to technical aspect/ wastage norms. While redeeming the application, RAs should check that the applicant has fulfilled all requirements as prescribed in policy/procedure including those in policy circulars issued from time to time or any other provisions under FTP/HBP for issuance of Advance Authorization and regularization of the case.
The committee went through the minutes of earlier meeting No. NC/3/MEET/Oct/202122/10 dated 12.11.2021, was actually held on was actually held on 26.11.2021.
MANUAL CASES
Following firm were called for attending Personal Hearing on 17.12.2021
| Sl. No. | Firm’sName |
|---|---|
| 1 | M/s Jubilant Generics Ltd, New Delhi |
| 2 | M/s Panacea Biotec Ltd., New Delhi |
| 3 | M/s Piramal Enterprises Ltd, Mumbai |
| 4 | M/s KLJ Plasticizers Limited, New Delhi |
| 5 | M/s J.B Chemicals & Pharmaceuticals Ltd, Mumbai |
| 6 | M/s S M Herbals Pvt Ltd, New Delhi |
| 7 | M/s Chirag Enterprise |
| Case No. | A-01 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s Jubilant Generics Ltd, CLA, New Delhi |
| HQ F. No. | 01/82/050/00331/AM19/DES-III<br>01/82/050/00821/AM19/DES-III |
| RLA F. No. | 05/23/040/00490/AM18<br>05/23/040/00087/AM19 |
| Advance Authorization No. and Date | 0510406024 dated 28.03.2018<br>0510406614 dated 25.05.2018 |
| Subject | Request of M/s Jubilant Generics Ltd, CLA, New Delhi for<br>revision in adhoc norms fixed against Advance Authorization<br>No. 0510406024 dated 28.03.2018 and 0510406614 dated<br>25.05.2018 |
| Decision:Shri B.P. Saxena, Deputy Manager –Exim attended the Personal Hearing on 17.12.2021 and<br>explained its case.<br>The Committee considered the case and it was observed that Norms Committee- 3 in its Meeting<br>No.08/82-ALC4/2019 dated 20.09.2019have already correctly ratified the adhoc norms and there is no need to<br>further revise the norms. Hence, the Committee decided torejectthe request of firm for revision in adhoc norms<br>fixed against Advance Authorization No. |
e adhoc norms and there is no need to<br>further revise the norms. Hence, the Committee decided torejectthe request of firm for revision in adhoc norms<br>fixed against Advance Authorization No. 0510406024 dated 28.03.2018 and 0510406614 dated 25.05.2018.<br>RA concerned maytake further necessaryaction asper above decision of NC.||
| Case No. | A-02 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s Jubilant Generics Ltd, CLA, New Delhi |
| HQ F. No. | 01/82/050/00615/AM20/DES-III<br>01/82/050/00378/AM20/DES-III |
| RLA F. No. | 05/23/040/00233/AM20<br>05/23/040/00152/AM20 |
| Advance Authorization No. and Date | 0510411821 dated 12.09.2019<br>0510411213dated 10.07.2019 |
| Subject | Request of M/s Jubilant Generics Ltd, CLA, New Delhi for<br>revision in adhoc norms fixed against Advance Authorization No.<br>0510411821 dated 12.09.2019 and 0510411213 dated 10.07.2019 |
| **Decision:**Shri B.P. Saxena, Deputy Manager –Exim attended the Personal Hearing on 17.12.2021 and has<br>informed that the norms fixed by NC-3 in its Meeting No.10/82-ALC4/2019 dated 29.11.2019 and 06/82-<br>ALC4/2019 dated 16.08.2019against Advance Authorization No. 0510411821 dated 12.09.2019 and 0510411213<br>dated 10.07.2019 are acceptable to them and they don’t need further revision of adhoc norms fixed against<br>Advance Authorization No. |
uthorization No. 0510411821 dated 12.09.2019 and 0510411213<br>dated 10.07.2019 are acceptable to them and they don’t need further revision of adhoc norms fixed against<br>Advance Authorization No. 0510411821 dated 12.09.2019 and 0510411213 dated 10.07.2019.<br>The Committee considered the request of firm and it was decided towithdrawthe case.<br>RA concerned maytake further necessaryaction asper above decision of NC.||
| Case No. | A-03 | |
|---|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 | |
| Date | 17.12.2021 | |
| Firm’sName | M/s Panacea Biotec Ltd., New Delhi | |
| HQ F. No. | 01/82/050/00171/AM20/DES-III | |
| 01/82/050/00354/AM20/DES-III | ||
| 01/82/050/00581/AM20/DES-III | ||
| 01/82/050/00693/AM20/DES-III | ||
| 01/82/050/00969/AM20/DES-III | ||
| RLA F. No. | 05/24/040/00086/AM20 | |
| 05/24/040/00217/AM20 | ||
| 05/24/040/00321/AM20 | ||
| 05/24/040/00358/AM20 | ||
| 05/24/040/00283/AM20 | ||
| Advance Authorization No. and Date | 0510410569 dated 14.05.2019 | |
| 0510411176 dated 08.07.2019 | ||
| 0510411723 dated 03.09.2019 | ||
| 0510412013 dated 03.10.2019 | ||
| 0510411569 dated 20.08.2019 | ||
| Subject | Request of M/s Panacea Biotaec Ltd, CLA, New Delhi for | |
| enhancement in wastage of norms in respect of adhoc norms | ||
| **fixed against Advance Authorization Nos. |
ed 20.08.2019**| |Subject||Request of M/s Panacea Biotaec Ltd, CLA, New Delhi for| |||enhancement in wastage of norms in respect of adhoc norms| |||fixed against Advance Authorization Nos. 0510410569 dated| |||14.05.2019, 0510411176 dated 08.07.2019, 0510411723 dated| |||03.09.2019, 0510412013 dated 03.10.2019 and 0510411569 dated| |||20.08.2019| |Decision:|The firm vide e-mail dated|01.12.2021was called for attending Personal Hearing on 17.12.2021.| |However, the Representative of firm vide e-mail dated 16.12.2021 has informed that an USFDA Audit is expected||| |to take place any time at their Baddi Unit and due to that their Scientist, who is also their Technical Representative||| |will not be able to attend the Personal Hearing on 17.12.2021.||| ||TheCommittee considered the request of firm and itwas decided todeferthe case.||
| Case No. | A-04 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s Piramal Enterprises Ltd, Mumbai |
| HQ F. No. | 01/82/050/01293/AM21/DES-III |
| 01/82/050/01361/AM21/DES-III | |
| RLA F. No. | 03/95/040/00074/AM21 |
| 03/95/040/00132/AM21 | |
| Advance Authorization No. and Date | 0310836193 dated 14.05.2020 |
| 0310836576 dated 08.06.2020 | |
| Subject | Request of M/s Piramal Enterprises Ltd, Mumbai for |
| enhancement in the quantity of import item in respect of adhoc | |
| norms fixed against Advance Authorization Nos. 0310836193 dated | |
| 14.05.2020 and 0310836576 dated 08.06.2020 |
or**| ||enhancement in the quantity of import item in respect of adhoc| ||norms fixed against Advance Authorization Nos. 0310836193 dated| ||14.05.2020 and 0310836576 dated 08.06.2020|
Decision: Shri Devesh Desai, GM-Exim and Shri Sunil Kumar Jain, General Manager – Production attended the Personal Hearing on 17.12.2021 and explained their case. The Committee after deliberations decided to revise the norms as under:
For Advance Authorization No. 0310836193 dated 14.05.2020
| Export Product | Qty. | Sl.<br>No. | Import items | Qty. |
|---|---|---|---|---|
| Bempedoic Acid and Ezetimibe Fixed Dose<br>Combination<br>Tablets<br>(Net<br>content<br>of<br>Bempedoic<br>Acid<br>514.8<br>kgs<br>and Ezetimibe 28.600 kgs in Total Export<br>Qty) (AA for Free of cost material as per Para<br>4.11 of HBP & Para 4.19 of FTP & RBI<br>Master<br>Circular<br>C-26<br>-<br>Disallowing<br>remittances for material being supplied free of<br>cost) | 1 Number | 1 | BEMPEDOICACID | 189.90mg |
| 2 | EZETIMIBE | 10.55 mg |
For Advance Authorization No. 0310836576 dated 08.06.2020
| Export Product | Qty. | Sl.<br>No. | Import items | Qty. |
|---|---|---|---|---|
| Bempedoic Acid and Ezetimibe Fixed Dose<br>Combination<br>Tablets<br>Net<br>content<br>of<br>Bempedoic<br>Acid<br>2403<br>kgs<br>and Ezetimibe 133.50 kgs in Total Export<br>Qty) (AA for Free of cost material as per Para<br>4.11 of HBP & Para 4.19 of FTP & RBI<br>Master<br>Circular<br>C-26<br>-<br>Disallowing<br>remittances for material being supplied free of<br>cost) | 1 Number | 1 | BEMPEDOICACID | 189.90mg |
| 2 | EZETIMIBE | 10.55 mg |
Note: The above norms are valid only for subject to fulfillment of following conditions: 1. Export Product being Patented Medicine, be filed with USFDA as an NDA (New Drug Application. 2. Export to USA and Europe only. 3. Firm holding Certificate of Manufacturing Exclusivity.
RA concerned may take further necessary action as per above decision of NC.
DA (New Drug Application. 2. Export to USA and Europe only. 3. Firm holding Certificate of Manufacturing Exclusivity.**
RA concerned may take further necessary action as per above decision of NC.
| Case No. | A-05 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s Piramal Enterprises Ltd, Mumbai |
| HQF. No. | 01/82/050/01200/AM21/DES-III |
| RLA F. No. | 03/95/040/01217/AM20 |
| Advance Authorization No. and Date | 0310835767 dated 21.04.2020 |
| Subject | Request of M/s Piramal Enterprises Ltd, Mumbai for enhancement<br>in the quantity of import item in respect of adhoc norms fixed against<br>Advance Authorization No. 0310835767 dated 21.04.2020 |
| **Decision:**Shri Devesh Desai, GM-Exim and Shri Sunil Kumar Jain, General Manager – Production attended the<br>Personal Hearing on 17.12.2021 and explained their case.<br>TheCommittee decided to defer the case forwant of comments from TE. |
| Case No. | A-06 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s Piramal Enterprises Ltd., Mumbai |
| HQF. No. | 01/82/050/01017/AM20/DES-III |
| RLA F. No. | 03/95/040/01020/AM20 |
| Advance Authorization No. and Date | 0310834270dated 17.01.2020 |
| Subject | Request of M/s Piramal Enterprises Ltd., Mumbai for enhancement<br>in the quantity of import item in respect of adhoc norms fixed against<br>**Advance Authorization No. |
d 17.01.2020| |Subject|Request of M/s Piramal Enterprises Ltd., Mumbai for enhancement<br>in the quantity of import item in respect of adhoc norms fixed against<br>Advance Authorization No. 0310834270 dated 17.01.2020| |**Decision:**Shri Devesh Desai, GM-Exim and Shri Sunil Kumar Jain, General Manager – Production attended the<br>Personal Hearing on 17.12.2021 and explained their case.<br>The Committee decided to defer the case for want of comments from TE.||
Case No. A-07 Meeting No. NC/3/MEET/Dec/202122/12 Date 17.12.2021 Firm’s Name M/s Piramal Enterprises Ltd., Mumbai HQ F. No. 01/82/050/01530/AM21/DES-III RLA F. No. 03/95/040/00268/AM21 Advance Authorization No. and Date 0310837588 dated 10.08.2020 Subject Request of M/s Piramal Enterprises Ltd., Mumbai for enhancement in the quantity of import item in respect of adhoc norms fixed against Advance Authorization No. 0310837588 dated 10.08.2020
Decision:
Decision: Shri Devesh Desai, GM-Exim and Shri Sunil Kumar Jain, General Manager – Production attended the Personal Hearing on 17.12.2021 and explained their case.
The Committee after deliberations decided to revise the norms as under:
| Export Product | Qty. | Sl. | Import items | Qty. |
|---|---|---|---|---|
| No. | ||||
| Bempedoic Acid and Ezetimibe Fixed Dose | 1 Number | 1 | BEMPEDOICACID | 189.90mg |
| Combination Tablets (Net content of | 2 | EZETIMIBE | 10.55 mg | |
| Bempedoic<br>Acid<br>2710.80<br>kgs<br>and | ||||
| Ezetimibe 150.6 kgs in Total Export Qty) | ||||
| (AA for Free of cost material as per Para | ||||
| 4.11 of HBP & Para 4.19 of FTP & RBI | ||||
| Master<br>Circular<br>C-26<br>-<br>Disallowing | ||||
| remittances for material being supplied free | ||||
| of cost) | ||||
| Note: The above norms are valid only for subject to fulfillment of following conditions: | ||||
| 1.<br>Export Product being Patented Medicine, be filed with USFDA as an NDA (New Drug | ||||
| Application. | ||||
| 2.<br>Export to USA and Europe only. | ||||
| 3.<br>Firm holding Certificate of Manufacturing Exclusivity. | ||||
| RA concerned may take further necessary action as per above decision of NC. |
Export to USA and Europe only.||||| |3.<br>Firm holding Certificate of Manufacturing Exclusivity.||||| |RA concerned may take further necessary action as per above decision of NC.|||||
| Case No. | A-08 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s Piramal Enterprises Ltd., Mumbai |
| HQ F. No. | 01/82/050/01547/AM21/DES-III<br>01/82/050/01407/AM21/DES-III |
| RLA F. No. | 03/95/040/00283/AM21<br>03/95/040/00153/AM21 |
| Advance Authorization No. and Date | 0310837743 dated 18.08.2020<br>0310836784 dated 22.06.2020 |
| Subject | Request of M/s Piramal Enterprises Ltd., Mumbai for enhancement in<br>the quantity of import item in respect of adhoc norms fixed against<br>Advance Authorization No. 0310837743 dated 18.08.2020 and<br>0310836784 dated 22.06.2020 |
| **Decision:**Shri Devesh Desai, GM-Exim and Shri Sunil Kumar Jain, General Manager – Production attended the<br>Personal Hearing on 17.12.2021 and explained their case.<br>The Committee decided to defer the case for want of comments from TE. |
i Sunil Kumar Jain, General Manager – Production attended the<br>Personal Hearing on 17.12.2021 and explained their case.<br>The Committee decided to defer the case for want of comments from TE.||
| Case No. | Case No. | A-09 | A-09 | A-09 | A-09 | |
|---|---|---|---|---|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 | |||||
| Date | 17.12.2021 | |||||
| Firm’sName | M/s KLJ Plasticizers Limited, New Delhi | |||||
| HQ F. No. | 01/82/050/02301/AM19/DES-III<br>01/82/050/00308/AM20/DES-III | |||||
| RLA F. No. | 05/23/040/00475/AM19<br>05/23/040/00125/AM20 | |||||
| Advance Authorization No. and Date | 0510409477 dated 25.01.2019<br>0510411049 dated 25.06.2019 | |||||
| Subject | Request of M/s KLJ PLASTICIZERS LIMITED, NEW DELHI<br>for enhancement in the quantity of import item No. 2 - SABUTOL<br>in respect of adhoc norms fixed against Advance Authorization<br>Nos. 0510409477 dated 25.01.2019 and 0510411049 dated<br>25.06.2019 | |||||
| **Decision:**Shri Shanti Lal Dagar, DGM-Fianance and Shri Vikas Gupta, AGM-Manufacturing . attended the<br>Personal Hearing on 17.12.2021 and explained their case.<br>The Committee considered the request of firm and it was decided to revise the adhoc norms for<br>under:<br>Export product<br>Qty.<br>Sl.<br>No.<br>Import items<br>Qty.<br>DI-BUTYL PHTHALATE<br>(GRADE-M) (DBP-M)<br>(PACKED IN 2554 NOS. |
ided to revise the adhoc norms for<br>under:<br>Export product<br>Qty.<br>Sl.<br>No.<br>Import items<br>Qty.<br>DI-BUTYL PHTHALATE<br>(GRADE-M) (DBP-M)<br>(PACKED IN 2554 NOS. OF HM-<br>HDPE DRUMS MADE OF HDPE<br>GRANULES (21,709.000 KGS.<br>WITHOUT WASTAGE)) (EACH<br>DRUM SHALL WEIGHT 8.5 KG<br>AND STORAGE CAPACITY<br>235.000KGS.)<br>1 kg<br>1.<br>PHTHALIC ANHYDRIDE<br>0.56 kg<br>2.<br>SABUTOL<br>0.595 kg<br>3.<br>HDPE<br>GRANULES<br>(TOTAL<br>WEIGHT<br>=<br>22,794.450 KGS.)<br>Relevant<br>as<br>per<br>packing policy<br>RA concerned maytake further necessaryaction asper above decision of NC.|||||| ||Export product|Qty.||Sl.<br>No.|Import items|Qty.| ||DI-BUTYL PHTHALATE<br>(GRADE-M) (DBP-M)<br>(PACKED IN 2554 NOS. OF HM-<br>HDPE DRUMS MADE OF HDPE<br>GRANULES (21,709.000 KGS.<br>WITHOUT WASTAGE)) (EACH<br>DRUM SHALL WEIGHT 8.5 KG<br>AND STORAGE CAPACITY<br>235.000KGS.)|1 kg||1.|PHTHALIC ANHYDRIDE|0.56 kg| |||||2.|SABUTOL|0.595 kg| |||||3.|HDPE<br>GRANULES<br>(TOTAL<br>WEIGHT<br>=<br>22,794.450 KGS.)|Relevant<br>as<br>per<br>packing policy| ||RA concerned maytake further necessaryaction asper above decision of NC.||||||
g**| |||||3.|HDPE<br>GRANULES<br>(TOTAL<br>WEIGHT<br>=<br>22,794.450 KGS.)|Relevant<br>as<br>per<br>packing policy| ||RA concerned maytake further necessaryaction asper above decision of NC.||||||
| Case No. | A-10 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s J.B Chemicals & Pharmaceuticals Ltd, Mumbai |
| HQF. No. | 01/82/050/01227/AM19/DES-III |
| RLA F. No. | 03/94/040/00298/AM19 |
| Advance Authorization No. and Date | 0310822175 dated 06.07.2018 |
| Subject | Request of M/s J.B Chemicals & Pharmaceuticals Ltd, Mumbai for<br>enhancement in the quantity of import item in respect of adhoc norms<br>fixed against Advance Authorization No. 0310822175 dated<br>06.07.2018 |
| Decision:Shri Parag C. Brahme, General Manager and Shri Mirar Khang, Sr. Exceutive – Production attended<br>the Personal Hearing on 17.12.2021 and explained thie case.<br>The Committee considered the case and it was decided to call for following information from the<br>firm:<br>(i)<br>Master Batch Manufacturing Record alongwith letter from Drug Controller<br>Authority. |
idered the case and it was decided to call for following information from the<br>firm:<br>(i)<br>Master Batch Manufacturing Record alongwith letter from Drug Controller<br>Authority.||
| Case No. | A-11 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s S M Herbals Pvt Ltd, CLA, New Delhi |
| HQF. No. | 01/82/050/00842/AM14/DES-III |
| RLA F. No. | 05/24/040/00239/AM14 |
| Advance Authorization No. and Date | 0510367886dated08.10.2013 |
| Subject | Request of M/s S M Herbals Pvt. Ltd., CLA, New Delhi for<br>review of norms in respect of adhoc norms fixed against Advance<br>Authorization No. 0510367886 dated 08.10.2013 |
| Decision:The firm vide e-mail dated01.12.2021was called for attending Personal Hearing on 17.12.2021.<br>However, the firm did not attend the Personal Hearing.<br>Hence, the Committee decided torejectthe case.<br>RA concerned maytake further necessaryaction asper above decision of NC. |
.2021.<br>However, the firm did not attend the Personal Hearing.<br>Hence, the Committee decided torejectthe case.<br>RA concerned maytake further necessaryaction asper above decision of NC.||
| Case No. | A-12 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s S M Herbals Pvt Ltd, CLA, New Delhi |
| HQF. No. | 01/82/050/00608/AM13/DES-III |
| RLA F. No. | 05/24/040/00147/AM13 |
| Advance Authorization No. and Date | 0510330512 dated 25.07.2012 |
| Subject | Request of M/s S M Herbals Pvt. Ltd., CLA, New Delhi for<br>review of norms in respect of adhoc norms fixed against Advance<br>Authorization No. 0510330512 dated 25.07.2012 |
| Decision:The firm vide e-mail dated01.12.2021was called for attending Personal Hearing on 17.12.2021.<br>However, the firm did not attend the Personal Hearing.<br>Hence, the Committee decided torejectthe case.<br>RA concerned maytake further necessaryaction asper above decision of NC. |
.2021.<br>However, the firm did not attend the Personal Hearing.<br>Hence, the Committee decided torejectthe case.<br>RA concerned maytake further necessaryaction asper above decision of NC.||
| Case No. | A-13 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| RLA’sName | M/s SM Herbals Pvt. Ltd., New Delhi |
| HQF. No. | 01/82/050/01111/AM14/DES-III |
| RLA F. No. | 05/24/040/00321/AM14 |
| Advance Authorization No. and Date | 0510347573dated 27.12.2013 |
| Subject | Request of M/s SM Herbals Pvt. Ltd., New Delhi for ratification<br>of norms under Para 4.7.6 of HBP Vol. I (2009-2014) against<br>Advance Authorization No. 0510347573 dated 27.12.2013 |
| Decision:The firm vide e-mail dated01.12.2021was called for attending Personal Hearing on 17.12.2021.<br>However, the firm did not attend the Personal Hearing.<br>Hence, the Committee decided torejectthe case.<br>RA concerned maytake further necessaryaction asper above decision of NC. |
.2021.<br>However, the firm did not attend the Personal Hearing.<br>Hence, the Committee decided torejectthe case.<br>RA concerned maytake further necessaryaction asper above decision of NC.||
| Case No. | A-14 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| Firm’sName | M/s Chirag Enterprise |
| HQ F. No. | 01/82/050/00950/AM18/DES-III<br>01/82/050/00506/AM19/DES-III<br>01/82/050/00408/AM19/DES-III<br>01/82/050/00683/AM20/DES-III<br>01/82/050/00901/AM20/DES-III |
| RLA F. No. | 24/24/040/00028/AM18<br>24/24/040/00048/AM18<br>24/24/040/00053/AM18<br>24/24/040/00028/AM20<br>24/24/040/00019/AM20 |
| Advance Authorization No. and Date | 2410042298 dated 01.11.2017<br>2410042385 dated 19.03.2018<br>2410042399 dated 10.04.2018<br>2410042868 dated 27.09.2019<br>2410042947 dated 12.12.2019 |
| Subject | Request of M/s Chirag Enterprise for enhancement in the quantity<br>of import item fixed against Advance Authorization No.<br>2410042298 dated 01.11.2017, 2410042385 dated 19.03.2018,<br>2410042399 dated 10.04.2018, 2410042868 dated 27.09.2019 and<br>2410042947 dated 12.12.2019 |
| Decision:The firm vide e-mail dated01.12.2021was called for attending Personal Hearing on 17.12.2021.<br>However, the Representative of firm vide e-mail dated15.12.2021has informed that oneofhis close relative has<br>been tested covid Positive recently and therefore he is in home isolation, hence he will not be able to attend the<br>Personal Hearing on 17.12.2021. |
*has informed that oneofhis close relative has<br>been tested covid Positive recently and therefore he is in home isolation, hence he will not be able to attend the<br>Personal Hearing on 17.12.2021. Accordingly, he has requested to grant them 45 days time to attend Personal<br>Hearing.<br>TheCommittee considered the request of firm and itwas decided todeferthe case.||
| Case No. | A-15 |
|---|---|
| MeetingNo. | NC/3/MEET/Dec/202122/12 |
| Date | 17.12.2021 |
| RLA’sName | M/s Chirag Enterprise |
| HQF. No. | 01/82/050/01529/AM19/DES-III |
| RLA F. No. | 24/24/040/00046/AM18 |
| Advance Authorization No. and Date | 2410042384 dated 19.03.2018 |
| Subject | Request of M/s Chirag Enterprise for enhancement in the quantity<br>of import item fixed against Advance Authorization No.<br>2410042384 dated 19.03.2018 |
| Decision:The firm vide e-mail dated01.12.2021was called for attending Personal Hearing on 17.12.2021.<br>However, the Representative of firm vide e-mail dated15.12.2021has informed that oneofhis close relative has<br>been tested covid Positive recently and therefore he is in home isolation, hence he will not be able to attend the<br>Personal Hearing on 17.12.2021. Accordingly, he has requested to grant them 45 days time to attend Personal<br>Hearing.<br>TheCommittee considered the request of firm and itwas decided todeferthe case. |
Meeting ended with thanks to Chair and participants
Verbatim extracted text (OCR/PDF). Older scans and tables may show extraction artifacts — verify against the original for anything you act on.
No analysis generated for this document yet (analysis runs over brief docs + on-demand). Run build_analysis.py --ids 7960 --apply.